Explore over 150 North America-based contract manufacturing organizations engaged in the contract services of manufacturing biologics products including antibodies, vaccines, recombinant products, cell & gene therapy products among others, starting from cell-line development to fill & finish.
The data provides detailed insights that are available nowhere in the market with the goal of assisting market players in advancing their priorities and investments, as well as accessing the competitive landscape.
The data is captured around 25 vital metrics including biologics manufacturer’s name, location, service offering capabilities, scale of manufacturing, technology platforms, products and subproducts manufactured, current & completed projects of CMOs, facility name, location, establishment year, facility size & capacity, annual production, batch size, bioprocessing equipment, bioreactors, expression system, manufacturing process type, regulatory compliance & certifications, sponsors & collaborations, future plans of CMOs and many other parameters. Complete list of parameters is provided in the following section.
High number of biologics manufacturing facilities in the US, makes North America the most dominating globally. The North America CMO market has about 31% of the global CMO capacity with largest segment held by process development service. Some of the key Biologics CMOs covered in this tracker are KBI Biopharma Inc, FloridaBiologix, Cognate BioServices, MassBiologics, Goodwin Biotechnology, VGXI, In, Cytovance Biologics, Inc., and many other key CMOs operating in North America.
The data is underpinned by user-friendly visuals to allow users to filter through within all the parameters to obtain any specific data such as CMOs by country, CMOs name, product manufacturing type, scale of manufacturing, regulatory compliance, bioreactor capacity & types, service offerings, facility size, expression system, manufacturing process mode, analytical and bioprocessing equipment, collaborators, suppliers.
This data provides easy to comprehend data for over 150 biologics manufacturers with in-house capabilities and expert service offerings to support you with end-to-end manufacturing process. We ensure delivery of highly-qualified research as we tap into our database of 62000+ life science professionals curated over a decade.
The data provides extensive data and analyses of biologics-focused contract manufacturing service providers and their manufacturing facilities. Through this data IMAPAC aims to assist organizations to keep track of CMOs in North-America, particularly in the US, identify any opportunities for strategic partnership or investments to speed biologics product to market.
Through this data, you are more likely to stay ahead of your competitors by keeping updated track of new and upcoming CMOs, expand your knowledge & expertise in biomanufacturing. Identify any opportunities for strategic partnerships or investments to speed biologics products to market.
The data is researched and validated using primary and secondary research. The data is collected through multiple scientific and non-scientific sources including live discussions with experts through IMAPAC’s events and research reports, survey polls, company websites, press releases, publicly available information, regulatory database and many more.
We have a database of key decision makers from the biopharma companies across the region. We host industry surveys with bioprocessing leaders of CMOs and Biopharma, and host primary interviews with Heads of Manufacturing, R&D, Process Development Heads and multiple stakeholders in the companies to gather data as well as validate that data using our primary research analysts.
Throughout the year, we keep in touch with the KOLs through telephonic Conversation, with Q&A sessions with high profile biopharma professionals, for example CSO/CTO profiles. Apart from telephonic conversations, we send a list of questions which these experts fill in detail and send back to us.
We have dedicated analysts who gather data. The data included is validated through primary research (interviews, phone calls) with stakeholders which is then validated by IMAPAC’s research analysts to ensure the accuracy of the data.